Product Information
Registration Status: ActiveSIN01490P
ATGAM INJECTION 50mg/ML is approved to be sold in Singapore with effective from 1988-05-23. It is marketed by PFIZER PTE LTD, with the registration number of SIN01490P.
This product contains Antilymphocyte Immunoglobulin (Horse) 50mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by PHARMACIA & UPJOHN CO in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions. There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).
Indication
For prevention of renal transplant rejection and for the treatment of aplastic anemia.
Toxicity
The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia.
Active Ingredient/Synonyms
Anti-thymocyte Globulin (Equine) | Anti-thymocyte globulin equine | eATG | equine ATG | Equine thymocyte immune globulin | hATG | Horse anti-thymocyte globulin | Horse ATG | Lymphocyte immune globulin anti-thymocyte globulin (equine) | Lymphocyte immune globulin, anti-thymocyte globulin | Antilymphocyte immunoglobulin (horse) |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.